Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect ® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)

Mohit Narang, MD, Rafat Abonour, MD, Brian G. M. Durie, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, James W. Hardin, PhD, Sundar Jagannath, MD, Howard R. Terebelo, DO, Lynne Wagner, PhD, Shankar Srinivasan, PhD, E. Dawn Flick, MPH. ScD, Faiza Zafar, MPAS, Amani Kitali, MBA, MPH, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 3156.

https://doi.org/10.1182/blood.V130.Suppl_1.3156.3156

Published: 2017

Journal Articles

Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA (NAA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Connect ® MM Registry

Cristina J. Gasparetto, MD, Rafat Abonour, MD, Sundar Jagannath, MD, Brian G. M. Durie, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, James W. Hardin, PhD, Lynne Wagner, PhD, Shankar Srinivasan, PhD, Amani Kitali, MBA, MPH, E. Dawn Flick, MPH, Faiza Zafar, MPAS, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 3101.

https://doi.org/10.1182/blood.V130.Suppl_1.3101.3101

Published: 2017

Journal Articles

Development of a Predictive Model of Multiple Myeloma (MM) Patient (pt) Outcomes Based on Treatment Class Transitions Using the Connect ® MMpatient Registry

Sundar Jagannath, MD, Robert M. Rifkin, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, Brian G. M. Durie, MD, James W. Hardin, PhD, Howard R. Terebelo, DO, Lynne Wagner, PhD, Mohit Narang, MD, Shankar Srinivasan, PhD, Ahmed YoussefAgha, PhD, Amani Kitali, MBA, MPH, Gail Larkins, RN, MBA, Amit Agarwal, MD PhD, Rafat Abonour, MD

Blood (2017) 130 (Supplement 1): 3122.

https://doi.org/10.1182/blood.V130.Suppl_1.3122.3122

Published: 2017

Journal Articles

Development of a Prognostic Model That Predicts 3- and 5-Year Overall Survival in Multiple Myeloma Using the Connect ® MM Patient Registry

Howard R. Terebelo, DO, Rafat Abonour, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, Brian G. M. Durie, MD, James W. Hardin, PhD, Sundar Jagannath, MD, Lynne Wagner, PhD, Mohit Narang, MD, Shankar Srinivasan, PhD, Lihua Yue, PhD, Faiza Zafar, MPAS, Amani Kitali, MBA, MPH, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 1842.

https://doi.org/10.1182/blood.V130.Suppl_1.1842.1842

Published: 2017

Journal Articles

Evaluation of Circulating Tumour DNA for the Mutational Characterisation of Multiple Myeloma

Andrew Spencer, Sridurga Mithraprabhu, Post doc, Malarmathy Ramachandran, Daniela Klarica, RN, Jay Hocking, MD, Laura Mai, Stephanie Walsh, David Broemeling, Andre Marziali, Anna Kalff, MD, Matthew Wiggin, Brian G. M. Durie, MD, Tiffany T. Khong, PhD

Blood (2015) 126 (23): 368.

https://doi.org/10.1182/blood.V126.23.368.368

Published: 2015

Journal Articles

Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study

Blood (2015) 126 (23): 4201.

https://doi.org/10.1182/blood.V126.23.4201.4201

Published: 2015

Journal Articles

Connect MM ® —the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease

Jatin J. Shah, MD, Rafat Abonour, MD, Brian G M Durie, MD, Jayesh Mehta, MD, Mohit Narang, MD, Howard Terebelo, DO, Cristina J Gasparetto, MD, Sachdev P. Thomas, MD, Kathleen Toomey, MD, James W Hardin, PhD, Shankar Srinivasan, PhD, Rosanna J. Ricafort, MD, Yasir Nagarwala, MD, Robert M. Rifkin, MD

Blood (2014) 124 (21): 2106.

https://doi.org/10.1182/blood.V124.21.2106.2106

Published: 2014

Journal Articles

A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone (CCyD) Prior to Autologous Stem Cell Transplant (ASCT) in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma

William I. Bensinger, MD, Robert Vescio, MD, Cristina Gasparetto, MD, Elber S. Camacho, MD, Rajneesh Nath, MD, Christina L. Gomes, MD, David D. Smith, PhD, Jatin J. Shah, Brian G. M. Durie, MD

Blood (2014) 124 (21): 4739.

https://doi.org/10.1182/blood.V124.21.4739.4739

Published: 2014

Journal Articles

A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Adam D. Cohen, MD, Emma C. Scott, MD, Michaela Liedtke, MD, Jonathan L. Kaufman, MD, Heather Landau, MD, David H. Vesole, MD PhD, Christina L. Gomes, MD, Cristina Gasparetto, MD, Suzanne Lentzsch, MD PhD, Michael Rosenzweig, MD, Vaishali Sanchorawala, MD, David D. Smith, PhD, Raymond L. Comenzo, MD, Brian G. M. Durie, MD

Blood (2014) 124 (21): 4741.

https://doi.org/10.1182/blood.V124.21.4741.4741

Published: 2014

Journal Articles

SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM)

Saad Z. Usmani, MD, Rachael Sexton, Sikander Ailawadhi, MD, Jatin J. Shah, Natalie S Callander, MD, Todd Zimmerman, MD, Jason Valent, MD, Michael Rosenzweig, MD, Brea C. Lipe, MD, Jeffrey Zonder, MD, Sandi Fredette, Brian G. M. Durie, MD, Antje Hoering, PhD, S. Vincent Rajkumar, MD, Paul G. Richardson, Robert Z. Orlowski, PhD MD

Blood (2014) 124 (21): 4762.

https://doi.org/10.1182/blood.V124.21.4762.4762

Published: 2014

Journal Articles

Connect MM®—the Multiple Myeloma (MM) Disease Registry: Incidence of Second Primary Malignancies (SPM)

Robert M. Rifkin, MD, Rafat Abonour, MD, Jatin J. Shah, MD, Jayesh Mehta, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Cristina J Gasparetto, MD, Sachdev P. Thomas, MD, Kathleen Toomey, MD, James W Hardin, PhD, Jane Jie Lu, MS, Laurie Kenvin, BSN, RN, Shankar Srinivasan, PhD, Rosanna J. Ricafort, MD, Yasir Nagarwala, MD, Brian G. M. Durie, MD

Blood (2014) 124 (21): 4749.

https://doi.org/10.1182/blood.V124.21.4749.4749

Published: 2014

Journal Articles

Impact of Novel Treatments on Multiple Myeloma Survival

David Robinson, Satyin Kaura, MSci, MBA, Daniel Kiely, Mohamad A. Hussein, MD, Knar Nersesyan, Brian G. M. Durie, MD

Blood (2014) 124 (21): 5676.

https://doi.org/10.1182/blood.V124.21.5676.5676

Published: 2014

Journal Articles

A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma

Jatin J. Shah, M.D., Edward A. Stadtmauer, MD, Rafat Abonour, MD, Adam D Cohen, MD, William I. Bensinger, MD, Cristina Gasparetto, MD, Jonathan L. Kaufman, MD, Suzanne Lentzsch, MD, PhD, Dan T. Vogl, MD, MSCE, Robert Z. Orlowski, M.D., Ph.D., Erica L. Kim, MPH, Marti B. McKinley, BSN, MBA, Brian G M Durie, MD

Blood (2012) 120 (21): 74.

https://doi.org/10.1182/blood.V120.21.74.74

Published: 2012

Journal Articles

New US Myeloma Registry (Connect MM® – The Multiple Myeloma Disease Registry): Features of Newly Diagnosed Patients In 2010

Brian G. M. Durie, MD, Jatin J. Shah, BS, MD, Rafat Abonour, MD, Cristina Gasperetto, MD, Jayesh Mehta, MD, Chris L. Pashos, PhD, Kathleen Toomey, MD, Mohit Narang, MD, Howard Terebelo, DO, Fernando Camacho, MD, Arlene S. Swern, PhD, Thomas K. Street, RPh, Kristen A. Sullivan, MBA, Robert M. Rifkin, MD

Blood (2010) 116 (21): 5032.

https://doi.org/10.1182/blood.V116.21.5032.5032

Published: 2010

Journal Articles

Variation In Health-Related Quality of Life (HRQOL) by ISS Stage and ECOG Status Among Multiple Myeloma Patients.

Chris L Pashos, PhD, Brian G. M. Durie, MD, Robert M. Rifkin, MD, Jatin J Shah, BS, MD, Thomas K. Street, RPh, Kristen A. Sullivan, MBA, Zeba M. Khan, PhD

Blood (2010) 116 (21): 3828.

https://doi.org/10.1182/blood.V116.21.3828.3828

Published: 2010

Journal Articles

Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations.

David C Johnson, BSc, Walter M Gregory, PhD, Nicholas J Dickens, DPhil, Brian A Walker, PhD, Alex J Szubert, MSc, Faith E Davies, MD, Brian G M Durie, MD, Brian G Van Ness, PhD, Gareth J Morgan, MD, PhD

Blood (2009) 114 (22): 426.

https://doi.org/10.1182/blood.V114.22.426.426

Published: 2009

NARROW

Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect ® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)

Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA (NAA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Connect ® MM Registry

Development of a Predictive Model of Multiple Myeloma (MM) Patient (pt) Outcomes Based on Treatment Class Transitions Using the Connect ® MMpatient Registry

Development of a Prognostic Model That Predicts 3- and 5-Year Overall Survival in Multiple Myeloma Using the Connect ® MM Patient Registry

Evaluation of Circulating Tumour DNA for the Mutational Characterisation of Multiple Myeloma

Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study

Connect MM ® —the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease

A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone (CCyD) Prior to Autologous Stem Cell Transplant (ASCT) in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma

A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis

SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM)

Connect MM®—the Multiple Myeloma (MM) Disease Registry: Incidence of Second Primary Malignancies (SPM)

Impact of Novel Treatments on Multiple Myeloma Survival

A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma

New US Myeloma Registry (Connect MM® – The Multiple Myeloma Disease Registry): Features of Newly Diagnosed Patients In 2010

Variation In Health-Related Quality of Life (HRQOL) by ISS Stage and ECOG Status Among Multiple Myeloma Patients.

Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only